Results 21 to 30 of about 52,437 (276)

Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

open access: yesCancer, 2020
The optimal treatment for advanced leiomyosarcoma is still debated. Given histotype‐specific prospective controlled data lacking, this study retrospectively evaluated doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, and doxorubicin alone as ...
L. D’Ambrosio   +27 more
semanticscholar   +1 more source

Laparoscopic liver resection for liver metastasis of leiomyosarcoma of the thigh: a case report

open access: yesSurgical Case Reports, 2022
Background Although there is no established treatment strategy for liver metastasis of leiomyosarcoma, liver resection has been reported to be effective in some cases.
Shoichi Tsuzaka   +13 more
doaj   +1 more source

Leiomyosarcoma of the pancreas [PDF]

open access: yesHPB, 2001
This is a single case report of a rare tumour, pancreatic leiomyosarcoma.A 44-year-old woman presented with a painless epigastric mass, and CT scan showed a cystic lesion of the head of pancreas. An associated epigastric mass was found to be a lipoma. Pancreatoduodenectomy was successfully performed.
Gerard V. Aranha, P.G. Deveaux, S. Yong
openaire   +3 more sources

Imaging Findings of Primary Adrenal Leiomyosarcoma: A Case Report

open access: yes대한영상의학회지, 2020
Leiomyosarcoma is a malignant tumor that typically originates from either the uterus or the retroperitoneum. Furthermore, primary adrenal leiomyosarcoma is an extremely rare condition.
Hye Ran Yoon, Dong Hee Park
doaj   +1 more source

Leiomyosarcoma of Uterine Cervix– A Case Report [PDF]

open access: yesNational Journal of Laboratory Medicine, 2016
Primary sarcomas of cervix are rare lesions constituting 1% of the malignant tumors of cervix. Leiomyosarcoma of cervix is the commonest sarcoma of the cervix with only few cases reported in literature. We present a case of cervical leiomyosarcoma in
Renu Thambi   +3 more
doaj   +1 more source

Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile

open access: yesCancers, 2020
Uterine Leiomyosarcoma (uLMS) is by far the most common type of uterine sarcoma, characterized by an aggressive clinical course, a heterogeneous genetic profile and a very scarce response to cytotoxic chemotherapy.
A. Astolfi   +11 more
semanticscholar   +1 more source

Integrative genomic and transcriptomic analysis of leiomyosarcoma

open access: yesNature Communications, 2018
Leiomyosarcoma (LMS) is an aggressive mesenchymal malignancy with few therapeutic options. The mechanisms underlying LMS development, including clinically actionable genetic vulnerabilities, are largely unknown.
Priya Chudasama   +40 more
semanticscholar   +1 more source

Leiomyosarcoma of the Penis [PDF]

open access: yesSarcoma, 2002
We report a case of a 78‐year‐old patient with penile leiomyosarcoma, treated by radical penectomy. Two years after the operation the patient is without evidence of local recurrence or metastatic disease.We also discuss the treatment options and attempt a review of the literature.
Konstantinos Yannakoyorgos   +6 more
openaire   +2 more sources

Sixteen year-old with leiomyosarcoma in a prior benign myomectomy site

open access: yesGynecologic Oncology Reports, 2019
Uterine leiomyosarcoma in a prior myomectomy site is a rare phenomenon. We report an unusual case of a leiomyosarcoma arising six months post myomectomy in a 16-year old female.
Jennifer A. Vaz   +10 more
doaj   +1 more source

Laparoscopic and endoscopic cooperative surgery for leiomyosarcoma of the stomach: a case report with a review of the literature

open access: yesSurgical Case Reports, 2021
Background Leiomyosarcoma is a rare tumor that could originate from the gastrointestinal tract, uterus, kidney, retroperitoneum, and the soft tissues of the extremities.
Toru Takagi   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy